Accelerating drug discovery
Maybridge has been at the forefront of innovative screening compound design for over 50 years, seeking to support the needs of the drug discovery scientist and their pursuit of novel molecules of pharmaceutical interest.
The Maybridge collection of screening compounds, widely recognized for its market-leading diversity and quality, aims to increase the success rates of your drug discovery research. We offer a comprehensive range of chemical products and services tailored to the pharmaceutical and biotechnology sectors.
Screening compounds and libraries
At the forefront of our portfolio of screening compounds and libraries for hit identification are a highly diverse set of over 53,000 hit-like
and lead-like molecules, and the fragment collection which includes 30,000 chemical fragments, a most useful tool that accelerates structure-based
A set of over 53,000 individually designed of hit-like and lead-like molecules used in screening campaigns.
A collection of pharmacophorically rich intermediates specifically designed for medicinal chemistry.
A library of over 30,000 chemical fragments designed to accelerate structure-based lead identification.